Human Acute Lymphoid Leukemia Peripheral Blood Mononuclear Cells (Relapsed/Refractory)

Description

Human Acute Lymphoid Leukemia Peripheral Blood Mononuclear Cells (ALL PBMC) (Relapsed/Refractory) are isolated from the peripheral blood of patients with relapsed/refractory acute lymphoblastic leukemia (ALL). These cells are primary and typically used at early passages to preserve disease-specific characteristics. These PBMCs contain leukemic lymphoblasts characterized by aberrant expression of markers such as CD19 and CD34, along with potential genetic abnormalities including Philadelphia chromosome (BCR-ABL1) or other kinase-activating mutations. The relapsed/refractory nature of these cells makes them particularly valuable for investigating therapeutic failure, minimal residual disease, and leukemia stem cell biology, as they demonstrate evolved resistance to conventional chemotherapies and targeted agents. In advanced disease modeling, these samples are essential for investigating therapeutic resistance, leukemia signaling pathways, gene expression profiles in relapsed ALL, disease progression and relapse monitoring, and for supporting the development and evaluation of novel therapies in refractory acute lymphoblastic leukemia.